Abdominal Aortic Junction Tourniquet (AAJT-S) for Non-compressible Torso Haemorrhage in the Prehospital and Emergency Room Setting

Abdominal Aortic Junction Tourniquet (AAJT-S) for Non-compressible Torso Haemorrhage A Prospective Multicentre-study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07274150

Enrollment

Registered

2025-12-10

Start date

2026-02-01

Completion date

2028-07-01

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exanguination, NCTH, Polytrauma

Keywords

NCTH, Exanguination, Aortic occlusion

Brief summary

This study seeks to evaluate the feasibility of a Abdominal Aortic Balloon Occlusion of the Aorta (AAJT-S) in exanguinating trauma patients with non-compressible truncal haemorrhage in the emergency room and the pre-hospital setting.

Detailed description

Much like REBOA, AAJT-S can potentially stop blood flow distal to the device and therefore improve proximal aortic perfusion, minimize haemorrhage and stabilize patients until definite surgical repair/bleeding control is feasible. In contrast to REBOA, there is no need of femoral access and therefore, appropriate training is easily achieved. This study seeks to gather further information on the benefits and potential harms of this intervention on a multicentre level.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Written consent of the participant after being informed 2. Aged, or believed to be aged, 18 years or above 3. Confirmed or suspected life-threatening lower body trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss) 4. Thought to benefit from trauma resuscitation with AAJT-S or REBOA zone III 5. Traumatic cardiac arrest

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
effective placement of the device	1 hour	cessation of bloodflow distal to the device

Secondary

Measure	Time frame	Description
Outcome Measure	30 days	30-day in hospital mortality
Complications	90 days	Occurrence of complications of device application
hemodynamic improvement after application	1 hour	lower hart rate / higher blood pressure (improvement in bpm/mmHg)

Countries

Austria

Contacts

Primary ContactGabriel Honnef, MD, PhD

gabriel.honnef@medunigraz.at+436509160890

Outcome results